OncoSec Medical, Inc.

In terms of biotech bankruptcies, the new year is starting off bleak. In the first few days of 2024 alone, Humanigen and Athersys both filed for bankruptcy. More biotech companies filed for bankruptcy in 2023 than any year since 2010, underscoring a brutal year defined by layoffs, company closures and pipeline reprioritizations, according to data from S&P Global Market Intelligence. 2023 eclipsed all other years by far, with 18 companies filing for protection compared to eight in 2022, which had previously held the record as the highest bankruptcy year. https://public.flourish.studio/visualisation/16736139/ The year kicked off with Sorrento Therapeutics filing Chapter 11 amid a legal battle with billionaire Patrick Soon-Shiong and his immunotherapy biotech NantCell. The company had $235 million in debt and had run out of options. Sorrento had been developing a generic rival to Bristol Myers Squibb’s Abraxane, which was the subject of the dispute with Soon-Shiong. As of November 2023, Sorrento had laid off its chief financial officer in the final step in the closure process, according to a Securities and Exchange Commission document. For Infinity Pharmaceuticals, an unsuccessful merger with MEI Pharma was the straw that broke the camel’s back. The cancer-focused biotech filed for Chapter 11 bankruptcy on Sept. 29, a move that followed a 75% workforce reduction in July. Infinity had looked for a strategic transaction to keep running trials for eganelisib, a midstage asset being assessed in multiple indications, including urothelial cancer and solid tumors. MEI Pharma appeared to offer the saving Infinity sought until MEI shareholders’ sunk the deal, with 51% of voters opposed to the transaction. OncoSec Medical, which filed in June, was forced to wrap up after a pivotal trial of an interleukin 12-encoding plasmid in combination with Merck & Co.’s Keytruda failed to meet the bar for success in objective response rate. The phase 2b trial was testing the med, called TAVO-EP, in patients with unresectable or metastatic melanoma who had progressed after treatment with an anti-PD-1 checkpoint inhibitor. The company filed for bankruptcy after defaulting on a $2 million loan. https://public.flourish.studio/visualisation/16735813/ Back to court In terms of biotech bankruptcies, the new year is starting off bleak. In the first few days of 2024 alone, Humanigen and Athersys both filed for bankruptcy. The move comes as no surprise for Humanigen, a monoclonal-antibody-focused biotech that had been considering bankruptcy since last summer after talks of a potential reverse merger fell through. The company was on its last leg, with only $3.1 million in the bank last March after its anti-human GM-CSF mAb failed to improve outcomes in hospitalized COVID-19 patients in 2022. This is not the first time Humanigen has gone to the bankruptcy courts. The company, then named KaloBios Pharmaceuticals, also filed in 2015 but managed to reorganize and survive the struggle, according to the S&P data. The company emerged from bankruptcy the following year, thanks to a $14 million equity financing that helped recapitalize the business. Humanigen also picked up rights to a rare disease treatment called benznidazole. The biotech’s name changed to Humanigen in August 2017. But financial troubles again hit the newly named company, forcing the offloading of benznidazole in December 2017 as part of an agreement to exchange loan obligations for equity. Humanigen shifted from rare diseases to immunotherapy and oncology and moved lenzilumab to the center of its pipeline. Lenzilumab never quite found its footing in the clinic, with Humanigen testing it in cancer, COVID-19, graft-versus-host disease and others. A second therapy, the EphA-3-targeted monoclonal antibody ifabotuzumab, was also in development as recently as August 2023. That August pipeline update was the last from Humanigen, and, in January, bankruptcy papers (PDF) were filed. The company now plans to sell off its assets in a bidding process. But before filing the bankruptcy work, Humanigen sold off its biopharma business to Taran Therapeutics, meaning the therapies will go on via a stalking horse bid. Taran picked up a portfolio of monoclonal antibodies, including lenzilumab, ifabotuzumab and HGEN005, for $20 million. The writing was also on the wall for Athersys after the stem cell therapy company suffered a series of clinical setbacks. Ultimately, disappointing phase 3 data for an ischemic stroke cell therapy triggered the biotech to sell off all assets and file for bankruptcy Jan. 5. The healthcare sector as a whole has kicked off the year in third place among bankruptcy filings by sector, according to S&P, behind industrials and consumer discretionary. While the pace of bankruptcies across all sectors declined to start the year, S&P noted that companies are still facing relatively high interest rates and a challenging labor market. Editor's note: Chart data sourced from S&P Global Market Intelligence. Graphics by Gabrielle Masson.

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- The "Global AI in Clinical Trials Market: Trends and Forecasts 2023-2035" report has been added to ResearchAndMarkets.com's offering. The global AI in clinical trials market is estimated to be worth $ 1.4 billion in 2023 and expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period. The process of successfully developing a novel therapeutic intervention is both time and cost intensive. In fact, it is estimated that a drug requires around 10 years and over $ 2.5 billion capital investment, before reaching the market. In this process, clinical trials play a crucial role for assessing the drug's efficacy and safety in humans. These trials account for nearly 50% of the time and capital expenditure during drug development. However, sponsors face financial burdens and significant delays in marketing drugs due to unsuccessful clinical trials. Over the past few decades, the success rate of a drug candidate advancing the clinical trials to obtaining marketing approval has remained relatively constant at approximately 10% - 20%. This can be attributed to the factors contributing to clinical stage intervention failure, including inadequate study design, incomplete patient recruitment, improper subject stratification and high rate of clinical trial participant attrition. In order to overcome these challenges and streamline the clinical trial processes, stakeholders in the pharmaceutical industry are exploring innovative solutions and strategies. One such innovative strategy involves integrating AI in drug development, which has the potential to revolutionize traditional methods, particularly in clinical trials. It is worth noting that artificial intelligence in clinical trials can help integrate and analyze large volumes of data, enabling trial sponsors to optimize future research initiatives. Additionally, by addressing issues related to trial design, patient recruitment and retention, site selection, data interpretation, and treatment evaluation, AI has the potential to enhance and refine the entire process of clinical drug development. Moreover, in the first nine months of 2021, more than $20 billion was invested into artificial intelligence companies focused on healthcare, exceeding the prior investment, which was around $15 billion in 2020. Therefore, with the rising interest of investors in this field, we anticipate the AI in clinical trials market to witness healthy growth during the forecast period. Key Market Insights The report features an extensive study of the current market landscape, market size and future opportunities associated with the AI in clinical trials market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the AI in clinical trials market report are briefly discussed below. Benefits and Growing Demand for Artificial Intelligence Solutions for Patient Recruitment and Clinical Data Analysis AI solutions have emerged as a promising tool in the drug development process. These AI tools help companies improve the accuracy and efficiency of testing, accelerate drug development and optimize clinical trial outcomes. In addition, leveraging AI software in clinical trials helps increasing patient recruitment and retention, reduces trial time and cost, and provides more accurate clinical data analysis, personalized medicine, trial design and real-time patient monitoring. It is worth highlighting that the ability of AI to automate and streamline labor-intensive tasks, improve decision-making processes, and identify patterns and trends in complex datasets has garnered significant attention and interest from stakeholders in the pharmaceutical industry. In May 2023, US based Owkin received letter of support from the European Medicines Agency (EMA) for the use of proprietary deep learning models for oncology clinical trial analysis; the company believes that this can reduce the clinical trial failure rates in randomized clinical trial. Further several artificial intelligence companies have developed AI-powered platforms that optimize patient identification for clinical trials. Additionally, AI algorithms can be trained to analyze large amounts of data in electronic health records to identify eligible participants. Owing to these applications and recognition of the immense potential of AI by researchers and sponsors, the demand for AI clinical trials is likely to continue to grow and transform the landscape of drug development by improving patient outcomes in clinical trials. Current Market Landscape of AI in Clinical Trials: AI Software and Service Providers The AI in clinical trials market landscape features a mix of large, mid-sized and small companies. Currently, around 130 players have the required expertise to offer various software and services to streamline clinical studies. Notably, at present, around 80% of these AI in clinical trials software and service providers are focusing on leveraging machine learning and deep learning algorithms, as they minimize data-based errors by accessing various data points simultaneously. Recent developments in this field indicate that the artificial intelligence companies in clinical trials are upgrading their capabilities to accommodate the current and anticipated demand for these software and services. Partnership and Collaboration Trends in the AI in Clinical Trials Market In recent years, several artificial intelligence companies have inked partnerships related to AI in clinical trials domain with other industry / non-industry players. It is worth highlighting that, since 2018, a significant number of strategic partnerships have been inked in the AI in clinical trials industry. It is worth highlighting that product / technology utilization and integration agreements are the most common types of partnerships inked by stakeholders in the AI clinical trials field. Owing to several advantages of artificial intelligence in clinical trials, stakeholders are acquiring other industry players offering AI solutions / AI software for different clinical trial applications in order to expand their capabilities and build a comprehensive product / service portfolio. In February 2023, ZS acquired Trials.ai, an intelligent study design company, to enhance its end-to-end solutions to reimagine study design for its clients. In addition, several big pharma companies, such as Bristol Myers Squibb, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Pfizer and Roche, have also taken partnership initiatives related to AI in clinical trials, indicating the promise and benefits that AI technology holds in clinical trials. Key Trends in the AI in Clinical Trials Market In the past six years, around 600 completed / ongoing clinical trials utilized AI tools and technologies for evaluating drugs / therapies for different therapeutic areas, indicating the substantial efforts made by researchers engaged in this domain. Further, most of the clinical studies were designed for the purpose of diagnostics and treatment. It is worth noting that the University of California, the National Institute of Allergy and Infectious Diseases, and Mayo Clinic are among the most active sponsors of completed / ongoing clinical trials involving AI solutions. Rise in Investment in AI in Clinical Trials Market The heightened interest in the AI in clinical trials market can be validated by the fact that, in the last five years, close to $2.5 billion has been invested in companies engaged in providing AI software and services for clinical trials by several investors based across the globe. The majority of the funds have been raised through venture rounds, followed by seed financing rounds. In addition, several big pharma players, such as Bristol Myers Squibb, Merck, Novartis, Pfizer and Sanofi have also invested in AI software and service providers for clinical trials. In June 2021, Antidote Technologies raised $23 million to expand its digital patient engagement programs and clinical trial recruitment services. AI in Clinical Trials Market Size Driven by the rising demand for artificial intelligence in clinical trials, lucrative opportunities are expected to emerge for players offering AI technology for clinical studies. The global market for AI in clinical trials is anticipated to grow at a significant pace, with a CAGR of 16% during the forecast period. Among the therapeutic areas for which AI tools are leveraged in clinical trials, oncological disorders are most likely to adopt these AI solutions for streamlining processes, such as patient recruitment and retention, trial design, site selection, clinical data analysis, patient monitoring and personalized treatment. In terms of end-users, biotechnology and pharmaceutical companies are likely to hold the majority share (75%) of the AI in clinical trials market. Key Artificial Intelligence Companies Supporting Clinical Trials Examples of the key companies engaged in the AI in clinical trials domain (the complete list of players is available in the full report) include (in alphabetic order) Acclinate, AiCure, Aidar Health, Aitia, A.I. VALI, Ancora.ai, Antidote Technologies, Beacon Biosignals, BUDDI.AI, ConcertAI, Curify, Deep 6 AI, ICON, Innoplexus, Massive Bio, Median Technologies, Novadiscovery, Owkin, PHASTAR, SiteRx and Viz.ai. This market report also includes an easily searchable excel database of all the AI software / AI solutions and service providers for clinical trials worldwide. Scope of the Report The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments. The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry. The report also features detailed transcripts of interviews held with various industry stakeholders: Danielle Ralic (Co-Founder, Chief Executive Officer and Chief Technology Officer, Ancora.ai) Wout Brusselaers (Founder and Chief Executive Officer, Deep 6 AI) Dimitrios Skaltsas (Co-Founder and Executive Director, Intelligencia) R. A. Bavasso (Founder and Chief Executive Officer, nQ Medical) Grazia Mohren (Head of Marketing), Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer, Science 37) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Key Topics Covered 1. PREFACE 1.1. Introduction 1.2. Key Market Insights 1.3. Scope of the Report 1.4. Research Methodology 1.5. Frequently Asked Questions 1.6. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Overview of Artificial Intelligence (AI) 3.3. Subfields of AI 3.4. Applications of AI in Healthcare 3.4.1. Drug Discovery 3.4.2. Drug Manufacturing 3.4.3. Marketing 3.4.4. Diagnosis and Treatment 3.4.5. Clinical Trials 3.5. Applications of AI in Clinical Trials 3.6. Challenges Associated with the Adoption of AI 3.7. Future Perspective 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. AI in Clinical Trials: AI Software and Service Providers Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Location of Headquarters 4.2.4. Analysis by Company Size and Location of Headquarters (Region) 4.2.5. Analysis by Key Offering(s) 4.2.6. Analysis by Business Model(s) 4.2.7. Analysis by Deployment Option(s) 4.2.8. Analysis by Type of AI Technology 4.2.9. Analysis by Application Area(s) 4.2.10. Analysis by Potential End-user(s) 5. COMPANY PROFILES 5.1. Chapter Overview 5.2. AiCure 5.3. Antidote Technologies 5.4. Deep 6 AI 5.5. Innoplexus 5.6. IQVIA 5.7. Median Technologies 5.8. Medidata 5.9. Mendel.ai 5.10. Phesi 5.11. Saama Technologies 5.12. Signant Health 5.13. Trials.ai 6. CLINICAL TRIAL ANALYSIS 6.1. Chapter Overview 6.2. Scope and Methodology 6.3. AI in Clinical Trials 6.3.1. Analysis by Trial Registration Year 6.3.2. Analysis by Number of Patients Enrolled 6.3.3. Analysis by Trial Phase 6.3.4. Analysis by Trial Status 6.3.5. Analysis by Trial Registration Year and Status 6.3.6. Analysis by Type of Sponsor 6.3.7. Analysis by Patient Gender 6.3.8. Analysis by Patient Age 6.3.9. Word Cloud Analysis: Emerging Focus Areas 6.3.10. Analysis by Target Therapeutic Area 6.3.11. Analysis by Study Design 6.3.12. Most Active Players: Analysis by Number of Clinical Trials 6.3.13. Analysis of Clinical Trials by Geography 6.3.14. Analysis of Clinical Trials by Geography and Trial Status 6.3.15. Analysis of Patients Enrolled by Geography and Trial Registration Year 6.3.16. Analysis of Patients Enrolled by Geography and Trial Status 7. PARTNERSHIPS AND COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models 7.3. AI in Clinical Trials: List of Partnerships and Collaborations 7.3.1. Analysis by Year of Partnership 7.3.2. Analysis by Type of Partnership 7.3.3. Analysis by Year and Type of Partnership 7.3.4. Analysis by Application Area 7.3.5. Analysis by Target Therapeutic Area 7.3.6. Analysis by Type of Partner 7.3.7. Most Active Players: Analysis by Number of Partnerships 7.3.8. Analysis by Geography 8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Types of Funding 8.3. AI in Clinical Trials: List of Funding and Investments 8.3.1. Analysis by Year of Funding 8.3.2. Analysis by Amount Invested 8.3.3. Analysis by Type of Funding 8.3.4. Analysis by Type of Funding and Amount Invested 8.3.5. Most Active Players: Analysis by Amount Raised and Number of Funding Instances 8.3.6. Leading Investors: Analysis by Number of Funding Instances 8.3.7. Analysis of Amount Invested by Geography 8.3.8. Analysis of Number of Funding Instances by Geography 8.4. Concluding Remarks 9. BIG PHARMA INITIATIVES 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Analysis by Year of Initiative 9.4. Analysis by Type of Initiative 9.5. Analysis by Application Area of AI 9.6. Analysis by Target Therapeutic Area 9.7. Benchmarking Analysis: Big Pharma Players 10. AI IN CLINICAL TRIALS: USE CASES 10.1. Chapter Overview 10.2. Use Case 1: Collaboration between Roche and AiCure 10.3. Use Case 2: Collaboration between Takeda and AiCure 10.4. Use Case 3: Collaboration between Teva Pharmaceuticals and Intel 10.5. Use Case 4: Collaboration between Unnamed Pharmaceutical Company and Antidote 10.6. Use Case 5: Collaboration between Unnamed Pharmaceutical Company and Cognizant 10.7. Use Case 6: Collaboration between Cedars-Sinai Medical Center and Deep 6 AI 10.8. Use Case 7: Collaboration between GlaxoSmithKline (GSK) and PathAI 10.9. Use Case 8: Collaboration between Bristol Myers Squibb (BMS) and Concert AI 11. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS 11.1. Chapter Overview 11.2. Unmet Needs in Clinical Trials 11.3. Key Assumptions and Methodology 11.4. Key Tools / Technologies 11.4.1. Blockchain 11.4.2. Big Data Analytics 11.4.3. Real-world Evidence 11.4.4. Digital Twins 11.4.5. Cloud Computing 11.4.6. Internet of Things (IoT) 11.5. Trends in Research Activity 11.6. Trends in Intellectual Capital 11.7. Extent of Innovation versus Associated Risks 11.8. Results and Discussion 11.9. Summary 12. COST SAVING ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Methodology 12.3. Overall Cost Saving Potential of AI in Clinical Trials, 2023-2035 12.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035 12.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035 12.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035 12.3.4. Cost Saving Potential in Patient Recruitment, 2023-2035 12.3.5. Cost Saving Potential in Patient Retention, 2023-2035 12.3.6. Cost Saving Potential in Staffing and Administration, 2023-2035 12.3.7. Cost Saving Potential in Site Monitoring, 2023-2035 12.3.8. Cost Saving Potential in Source Data Verification, 2023-2035 12.3.9. Cost Saving Potential in Other Procedures, 2023-2035 13. MARKET SIZING AND OPPORTUNITY ANALYSIS 13.1. Chapter Overview 13.2. Forecast Methodology and Key Assumptions 13.3. Global AI in Clinical Trials Market, 2023-2035 13.3.1. AI in Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035 13.3.2. AI in Clinical Trials Market: Distribution by Target Therapeutic Area, 2023 and 2035 13.3.3. AI in Clinical Trials Market: Distribution by End-user, 2023 and 2035 13.3.4. AI in Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035 14. CONCLUSION 15. EXECUTIVE INSIGHTS 16. APPENDIX I: TABULATED DATA 17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned AbbVie Accelmed Accenture Acclinate Actelion Pharmaceuticals Adara Ventures AG Mednet Agent Health A.I. VALI AiCure Aidar Health AITIA AKESOgen AKRN Scientific Consulting (acquired by NAMSAN) Alexandria Venture Investments Alira Health AliveCor AllianceBernstein Alliance for Clinical Trials in Oncology Allucent Alpha MD ALS Association Alter Venture Partners Amadeus Capital Partners Amber Specialty Pharmacy American Society of Clinical Oncology (ASCO) Amgen Amgen Ventures Amplify Ancora.ai Anthem Anthemis Exponential Ventures Antidote Technologies Aperio APEX Digital Health APEX Ventures Arondor Artificial Intelligence in Medicine (AIM) (a subsidiary of Inspirata) ArtiQ Arvinas Asahi Kasei Ascension Ventures Aspen Insights Assistance Publique Hopitaux de Paris AstraZeneca ATAI Life Sciences AV8 Ventures Avalanche Venture Capital Avident Health Avira Digital Aviva Ventures Avon Baird Capital Baron Davis Enterprises Beacon Biosignals BEPATIENT Beyond Celiac Big Pi Ventures Bioforum Biofourmis Bioinfogate (acquired by Clarivate) Biomatics Capital Biomedical Advanced Research and Development Authority (BARDA) Blue Heron Capital Boehringer Ingelheim Boehringer Ingelheim Venture Fund (BIVF) Bold Capital Partners Bolton NHS Foundation Trust BootstrapLabs Boreal Ventures Bpifrance Brainomix Brainpan Innvovations Bridge Biotherapeutics Bristol Myers Squibb (BMS) Brite Health Bronze Valley BUDDI.AI BullFrog AI Cambridge Cognition Canary Speech Carebox Carenity (acquired by EvidentIQ) Carle Health Carlyle Casdin Capital Cathay Innovation Cavendish Impact Foundation (CIF) Cedar Health Research Celgene CellCarta Central Ohio Primary Care Physicians (COPC) The Centre for Aging + Brain Health Innovation (CABHI ) Cerba Research Chainlink Charterhouse Capital Partners Chartline Capital Partners ChemAxon Children's Oncology Group (COG) Chimera Partners Cigna Ventures CIMS Global Citeline ( a subsidiary of Norstella) Clario Clarivate ClearPoint Investment Partners Clinerion Clinevo Technologies clinicalAI CliniOps Clinithink ClinScape ClinTex CMIC Group Cognizant Community Health Network ConcertAI Constant Companion Creadev Crestle.ai (acquired by Doc.ai) Crista Galli Ventures Cumulus Neuroscience Curenetics Curify.ai CVS Health Dassault Systemes DataON Datavant DCM Ventures DCVC Bio Debiopharm Decibel Therapeutics Declaration Partners Deep 6 AI Deep Lens (acquired by Paradigm) DeepTrial Defense Health Agency Dementia Discovery Fund (DDF) Department of Veteran Affairs Deutsche Investitions und Entwicklungsgesellschaft (DEG) DiA Imaging Analysis doc.ai (acquired by Sharecare) Dong-A Socio Holdings EBSCO Information Services Echo Health Ventures EDBI Edison Partners Eight Roads Ventures eimageglobal EIT Health Elliott Investment Management Entrepreneur First Epilepsy Study Consortium Ergomed Erlanger Health System ERYTECH Espresso Capital Eugene M. Lang Foundation European Commission European Investment Bank European Regional Development Fund (ERDF) Excelra Experimental Cancer Medicine Centre (ECMC) Experimind Faber fathom it group FinLab EOS VC Fund First Analysis Corporation First Trust Capital Partners Florida Cancer Affiliates Folklore Ventures Fosun RZ Capital GE Healthcare Genentech General Atlantic General Catalyst Genoa Ventures Genomenon Genpro Research GlaxoSmithKline (GSK) Global Alzheimer's Platform Foundation Gloucestershire Cancer Alliance (SWAG) Google GV (formerly Google Ventures) Greater Gift Grey Sky Venture Partners Grove Ventures GSR Ventures Guy's and St Thomas' NHS Foundation Trust H1 H2O.ai Halo Health Hambro Perks Healint Healthix HealthMatch HealthVerity Hematology-Oncology Associates of Central New York (HOA) Jiangsu Hengrui Pharmaceuticals Herefordshire and Worcestershire Health and Care NHS Trust Heritage Medical Group Highline Sciences HCLTech Horizon Therapeutics Human API IBM iClusion ICON IKJ Capital iLoF IMA Group IMNA Solutions ImpactAssets Inato Indegene iNDX.Ai Inflection Biosciences Innoplexus Innovaderm Innovatrix Capital Insight Partners Insilico Medicine Inspirata Inspire Intel Intel Capital (a subsidiary of Intel) Intelligencia.ai Intermountain Ventures Investissement Quebec Iowa First Capital Fund Iowa Innovation Acceleration Fund IQ Capital IQVIA IXICO Janssen Pharmaceuticals Jianke Johns Hopkins University Johnson & Johnson Karyopharm Therapeutics Keosys Khosla Ventures King's Health Partners Kinship Kleiner Perkins Kognitic Labcorp Lambda Therapeutic Research LaunchCapital Launch Therapeutics LBO France Leal Health Legit.Health LEO Pharma Leukemia & Lymphoma Society Lieber Institute for Brain Development Life Image (acquired by Intelerad Medical SystemsT ) LifeArc Lightship Linguamatics (a subsidiary of IQVIA) Liquid 2 Ventures LMK Clinical Research Consulting Lokavant (a subsidiary of Roivant Sciences) LSU Health New Orleans Lunar Ventures M12 (formerly known as Microsoft Ventures) Massachusetts General Hospital Massive Bio MassMutual Ventures Matrix Capital Management Matrix Partners Maverick Ventures Maxer Consulting Mayfield Fund Mayo Clinic Mayo Clinic Ventures (a subsidiary of Mayo Clinic) McKesson Ventures (a subsidiary of McKesson) Medable Median Technologies Medica Medical Research Network (MRN) Medidata Solutions mediri Medpace MEDSOFT Medtronic Memorial Sloan Kettering Cancer Center (MSK) Mendel.ai Menlo Ventures Merck Merck Global Health Innovation Fund (Merck GHI) (a subsidiary of Merck) Microsoft Millennium Technology Value Partners Mitsui Moderna MSD Global Health Innovation Fund (MGHIF) MTIP Mubadala Capital Nanox National Cancer Institute (NCI) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Mental Health (NIMH) National Minority Health Association (NMHA) NEC NEC OncoImmunity (a subsidiary of NEC) NeoGenomics NetraMark NeuroEndocrine Cancer Australia New Enterprise Associates New Leaf Venture Partners Nex Cubed Next Level Ventures nference NJF Capital Nor-Tech North American Science Associates (NAMSA) Northpond Ventures Nova Discovery Novartis Novoic Novotech nQ Medical Nucleai NuvoAir Oak HC/FT Obvious Ventures Ocala Oncology Octopus Ventures Olive Tree OMRON Healthcare OncoBay Clinical OncoSec Medical One Nucleus OneStudyTeam Openspace Ventures Opyl Oracle Otium Venture ?URA Health Overline Venture Capital Owkin Oxford Finance University of Oxford Innovation Fund (UOIF) P1vital P360 P3Life Paige AI Palisades Growth Capital Pancare Foundation Pangaea Data Paradigm Parexel Parkwalk Advisors Partech Passage AI Patchai (acquired by Alira Health) PathAI Patient iP PatientPoint PatienTrials Patiro Pear Therapeutics Pepgra Perceiv AI Perceptive Advisors Perthera.ai Pfizer Pfizer Ventures (a subsidiary of Pfizer) Pharmamodelling Phastar phaware Phesi physIQ Plug and Play Ventures Point72 Ventures Population Health Partners PPC (merged with Novotech) PRA Health Sciences Precipio Prime Capital Pritzker Group ProofPilot Propeller Health Protocols.io PWNHealth Qmetrics Technologies Qualcomm Ventures Quality Cancer Care Alliance Network (QCCA) Quibim Quiet Capital Qure.ai Qwince Radical Ventures RadMD (acquired by Medica Group) Raylytic re.Mind Capital RealTime Software Solutions Red Abbey Labs Reify Health Remarque Systems Renmin Hospital of Wuhan University Rev1 Ventures Revo Capital Revolution Growth Risklick Rittenhouse Ventures Roche Roivant Sciences Royal Philips Rural Vitality Fund Rymedi Saama Technologies San Raffaele Hospital Sanofi Sanofi Ventures (a subsidiary of Sanofi) Scale Ventures Science37 Scipher Medicine Self-Care Catalysts Semicrol sensedat Sensyne Health Sequoia India Serena and Fly Ventures ServiceNow Servier SGInnovate Shandong University Sierra Ventures Sigmasoft Signant Health Silicon Valley Bank (SVB) SimBioSys Singtel Innov8 SiteGround Capital SiteRx Sixth Street Small Business Innovation Research (SBIR) Smedvig Capital SoftBank Vision Fund Somerset Sopris Capital SOSV Sourcia Southern Oncology Specialists Sozo Ventures SpringRock Ventures Square Peg Square Peg Capital Stanford Angels Stratus SubjectWell Sway Ventures SyMetric Symphony Clinical Research (acquired by ICON) SymphonyAI Syneos Health Synetro Synexus System Applications and Products in Data Processing (SAP) T. Rowe Price Taliaz Talkdesk Tamarind Hill Fund Teal Ventures Tech Transfer UPV TEDCO's Seed Fund Tempus Tencent Holdings Tenthpin TeraRecon TFS Services The Angels' Forum ThoughtSphere THREAD Tiger Global Management Timberline Holding TissueTech Translational Drug Development (TD2) TransPerfect Life Sciences Trialbee Trials.ai (acquired by ZS Associates) TrialSense Tribeca Venture Partners TriNetX TT Capital Partners TTi Health Research & Economics U.S. Food and Drug Administration (FDA) U.S. Veteran's Affairs UCB Biopharma UK Future Fund Underscore Venture Capital UnityPoint Health Ventures University of California University of Pennsylvania University of Pittsburgh Unlearn.AI Vastrax VeriSIM VersaTrial Vertex Ventures Veterans Prostate Cancer Awareness (VPCa) VIDA Viroclinics-DDL (acquired by Cerba HealthCare) VirTrial Vivoryon Therapeutics Viz.ai WallachBeth Capital WCG Clinical Wefight Wiley Winterlight Labs Wittington Ventures Worldwide Clinical Trials WP Global Partners XpertPatient Zola Global Investors ZS Associates For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Online auction by Tiger Group and Liquidity Services features advanced biotech equipment used for cancer-fighting immunotherapy research in San Diego SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- By order of a U.S. bankruptcy court, Tiger Group and Liquidity Services on Aug. 10 will auction OncoSec Medical Inc.'s former immunotherapy laboratory and R&D facility in San Diego. The biotechnology company, which focused on developing intertumoral immunotherapies to target cancer cells by stimulating patients' immune systems, filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware this past June. Continue Reading The sale features a BD LSRFortesa X-20 Cell Analyzer with HTS On August 10, A wide range of assets from OncoSec Medical Inc.'s former immunotherapy laboratory and R&D center in San Diego, CA will be available by auction from Tiger Group and Liquidity Services. Lots in the timed, online auction for OncoSec begin to close on Thursday, August 10, at 10:25 a.m. (PT). Bidding is underway at SoldTiger.com and Liquidity Services' AllSurplus.com marketplace. In the fight against cancer, OncoSec earned national attention for its proprietary TAVO™ electroporation platform. The company's immunotherapy research, carried out at its R&D facility in San Diego, required an extensive amount of cutting-edge and general lab equipment. "All told, online bidders will find 148 lots of clean, well-maintained biopharma assets in the online auction," noted John Coelho, Senior Director, Tiger Commercial & Industrial. "It's a rare opportunity for operators in this fast-moving and highly competitive space." The assets include: microscopes, cell profilers, incubators, and thermomixers safety cabinets, refrigerators, ultra-low-temperature freezers and benchtop centrifuges autoclaves, cell-imaging systems, cell profilers and advanced molecular imagers thermal cyclers, and cryogenic and/or nitrogen tank and storage systems digital dry-bath block heaters, oscilloscopes, force testers, electroporators and generators, and much more. "Extremely well-respected brands are represented in this sale, including the likes of Nexcelom Bioscience, Zeiss, Thermo Scientific, Fisher Scientific, Protein Simple, Tuttnauer, and NanoString Technologies," added Nick Jimenez, Vice President of Global Business Development, Liquidity Services. Highlights include BioRad CFX96 qPCR (2) Eppendorf microfuge 5424R (refrigerated) (8) SII Lago in vivo imaging device Stacked MaxQ 8000 orbital bacterial shakers (2) NanoString MAX system BD Fortessa X-20 flow cytometer Tuttnauer autoclave General lab equipment includes hot plates, stirrers, shakers, pipettes and pipette aids, glass and plasticware, along with laboratory consumables and wire racking. The auction features a total of 47 lots of office furniture, IT equipment and miscellaneous support equipment. Office assets include caster lab stools and chairs, stainless-steel tables, cabinets, shelving, work tables, breakroom appliances, wooden chairs and office chairs. "With respect to IT and electronics, there are computers, monitors, TVs, printers—including a 3D printer—and a server rack, among other items," Coehlo noted. "Bidders also will find general tools like drill presses that are in great condition." On-site inspections are available on Wednesday, August 9, by appointment only. To arrange an inspection or obtain other information, email: [email protected] or call (805) 497-4999. For asset photos, descriptions, and other information, visit: or… In addition, Sherwood Partners, Inc., has been retained to offer OncoSec's intellectual property assets for sale. "OncoSec has dedicated years of expertise to develop innovations with the potential to reshape cancer treatment and diagnostics," noted Molly Froschauer, Senior Vice President, Sherwood Partners. "The patents, proprietary technologies and research data in this portfolio are a tremendous opportunity for a wide array of medical research and biotech companies." For more information, call (310) 295-1530 or email [email protected]. About Tiger Group Tiger Capital Group provides asset valuation, advisory and disposition services to a broad range of retail, wholesale, and industrial clients. With over 40 years of experience and significant financial backing, Tiger's seasoned professionals help clients identify the underlying value of assets, monitor asset risk factors and, when needed, provide capital or convert assets to capital quickly and decisively. Tiger maintains offices in New York, Boston, Los Angeles, Chicago, Houston and Toronto. About Liquidity Services Liquidity Services operates the world's largest B2B e-commerce marketplace platform for surplus assets with over $10 billion in completed transactions to more than five million qualified buyers and 15,000 corporate and government sellers worldwide. The company supports its clients' sustainability efforts by helping them extend the life of assets, prevent unnecessary waste and carbon emissions, and reduce the number of products headed to landfills. Media Contacts: At Tiger Group, Maria Hoang, (805) 497-4999, [email protected]. At Jaffe Communications, Elisa Krantz, (908) 789-0700, [email protected]. SOURCE Tiger Group